Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic

Alexander Bukreyev, Joshua M. DiNapoli, Lijuan Yang, Brian R. Murphy, Peter L. Collins

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

We previously used human parainfluenza virus type 3 (HPIV3) as a vector to express the Ebola virus (EBOV) GP glycoprotein. The resulting HPIV3/EboGP vaccine was immunogenic and protective against EBOV challenge in a non-human primate model. However, it remained unclear whether the vaccine would be effective in adults due to preexisting immunity to HPIV3. Here, the immunogenicity of HPIV3/EboGP was compared in HPIV3-naive and HPIV3-immune Rhesus monkeys. After a single dose of HPIV3/EboGP, the titers of EBOV-specific serum ELISA or neutralization antibodies were substantially less in HPIV3-immune animals compared to HPIV3-naive animals. However, after two doses, which were previously determined to be required for complete protection against EBOV challenge, the antibody titers were indistinguishable between the two groups. The vaccine virus appeared to replicate, at a reduced level, in the respiratory tract despite the preexisting immunity. This may reflect the known ability of HPIV3 to re-infect and may also reflect the presence of EBOV GP in the vector virion, which confers resistance to neutralization in vitro by HPIV3-specific antibodies. These data suggest that HPIV3/EboGP will be immunogenic in adults as well as children.

Original languageEnglish (US)
Pages (from-to)290-298
Number of pages9
JournalVirology
Volume399
Issue number2
DOIs
StatePublished - Apr 10 2010
Externally publishedYes

Fingerprint

Ebola Vaccines
Human parainfluenza virus 3
Paramyxoviridae Infections
Respiratory System
Haplorhini
Viruses
Ebolavirus
Vaccines

Keywords

  • Antibody
  • Ebola
  • Immunity
  • Immunogenicity
  • Intranasal vaccination
  • Monkey
  • Mucosal vaccination
  • Vaccine
  • Vaccine vector
  • Virus

ASJC Scopus subject areas

  • Virology

Cite this

Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. / Bukreyev, Alexander; DiNapoli, Joshua M.; Yang, Lijuan; Murphy, Brian R.; Collins, Peter L.

In: Virology, Vol. 399, No. 2, 10.04.2010, p. 290-298.

Research output: Contribution to journalArticle

Bukreyev, Alexander ; DiNapoli, Joshua M. ; Yang, Lijuan ; Murphy, Brian R. ; Collins, Peter L. / Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. In: Virology. 2010 ; Vol. 399, No. 2. pp. 290-298.
@article{e28ecdb4a22746158576c36fdc27a62e,
title = "Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic",
abstract = "We previously used human parainfluenza virus type 3 (HPIV3) as a vector to express the Ebola virus (EBOV) GP glycoprotein. The resulting HPIV3/EboGP vaccine was immunogenic and protective against EBOV challenge in a non-human primate model. However, it remained unclear whether the vaccine would be effective in adults due to preexisting immunity to HPIV3. Here, the immunogenicity of HPIV3/EboGP was compared in HPIV3-naive and HPIV3-immune Rhesus monkeys. After a single dose of HPIV3/EboGP, the titers of EBOV-specific serum ELISA or neutralization antibodies were substantially less in HPIV3-immune animals compared to HPIV3-naive animals. However, after two doses, which were previously determined to be required for complete protection against EBOV challenge, the antibody titers were indistinguishable between the two groups. The vaccine virus appeared to replicate, at a reduced level, in the respiratory tract despite the preexisting immunity. This may reflect the known ability of HPIV3 to re-infect and may also reflect the presence of EBOV GP in the vector virion, which confers resistance to neutralization in vitro by HPIV3-specific antibodies. These data suggest that HPIV3/EboGP will be immunogenic in adults as well as children.",
keywords = "Antibody, Ebola, Immunity, Immunogenicity, Intranasal vaccination, Monkey, Mucosal vaccination, Vaccine, Vaccine vector, Virus",
author = "Alexander Bukreyev and DiNapoli, {Joshua M.} and Lijuan Yang and Murphy, {Brian R.} and Collins, {Peter L.}",
year = "2010",
month = "4",
day = "10",
doi = "10.1016/j.virol.2010.01.015",
language = "English (US)",
volume = "399",
pages = "290--298",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic

AU - Bukreyev, Alexander

AU - DiNapoli, Joshua M.

AU - Yang, Lijuan

AU - Murphy, Brian R.

AU - Collins, Peter L.

PY - 2010/4/10

Y1 - 2010/4/10

N2 - We previously used human parainfluenza virus type 3 (HPIV3) as a vector to express the Ebola virus (EBOV) GP glycoprotein. The resulting HPIV3/EboGP vaccine was immunogenic and protective against EBOV challenge in a non-human primate model. However, it remained unclear whether the vaccine would be effective in adults due to preexisting immunity to HPIV3. Here, the immunogenicity of HPIV3/EboGP was compared in HPIV3-naive and HPIV3-immune Rhesus monkeys. After a single dose of HPIV3/EboGP, the titers of EBOV-specific serum ELISA or neutralization antibodies were substantially less in HPIV3-immune animals compared to HPIV3-naive animals. However, after two doses, which were previously determined to be required for complete protection against EBOV challenge, the antibody titers were indistinguishable between the two groups. The vaccine virus appeared to replicate, at a reduced level, in the respiratory tract despite the preexisting immunity. This may reflect the known ability of HPIV3 to re-infect and may also reflect the presence of EBOV GP in the vector virion, which confers resistance to neutralization in vitro by HPIV3-specific antibodies. These data suggest that HPIV3/EboGP will be immunogenic in adults as well as children.

AB - We previously used human parainfluenza virus type 3 (HPIV3) as a vector to express the Ebola virus (EBOV) GP glycoprotein. The resulting HPIV3/EboGP vaccine was immunogenic and protective against EBOV challenge in a non-human primate model. However, it remained unclear whether the vaccine would be effective in adults due to preexisting immunity to HPIV3. Here, the immunogenicity of HPIV3/EboGP was compared in HPIV3-naive and HPIV3-immune Rhesus monkeys. After a single dose of HPIV3/EboGP, the titers of EBOV-specific serum ELISA or neutralization antibodies were substantially less in HPIV3-immune animals compared to HPIV3-naive animals. However, after two doses, which were previously determined to be required for complete protection against EBOV challenge, the antibody titers were indistinguishable between the two groups. The vaccine virus appeared to replicate, at a reduced level, in the respiratory tract despite the preexisting immunity. This may reflect the known ability of HPIV3 to re-infect and may also reflect the presence of EBOV GP in the vector virion, which confers resistance to neutralization in vitro by HPIV3-specific antibodies. These data suggest that HPIV3/EboGP will be immunogenic in adults as well as children.

KW - Antibody

KW - Ebola

KW - Immunity

KW - Immunogenicity

KW - Intranasal vaccination

KW - Monkey

KW - Mucosal vaccination

KW - Vaccine

KW - Vaccine vector

KW - Virus

UR - http://www.scopus.com/inward/record.url?scp=77249161128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249161128&partnerID=8YFLogxK

U2 - 10.1016/j.virol.2010.01.015

DO - 10.1016/j.virol.2010.01.015

M3 - Article

VL - 399

SP - 290

EP - 298

JO - Virology

JF - Virology

SN - 0042-6822

IS - 2

ER -